Table 1.

Burkholderia isolates used in this study.

Isolate	Description and reference	MIC (μg/ml kanamycin)	Virulence in mice by i.p. route
B. pseudomallei
K96243	Clinical isolate from Thailand, sequenced strain [26]	128	MLD = 262 (i.p.) [7]
576	Clinical isolate from Thailand [28]	128	MLD = 80 (i.p.) [7]
708a	Gentamicin-sensitive isolate from Thailand [9]	16	MLD = 2.3 × 103 (i.p.) [7]
B. thailandensis
E264	Environmental isolate, sequenced strain [10,37]	128	1/10 survivors at 107 cfu [16]
Phuket 4W-1	Water isolate from Thailand [38]	128	2/10 survivors at 107 cfu [16]
CDC3015869	Clinical isolate from Texas; abbreviated as CDC301 [39]	128	8/10 survivors at 107 cfu [16]
CDC2721121	Clinical isolate from Louisiana; abbreviated as CDC272 [39]	128	10/10 survivors at 107 cfu [16]
B. oklahomensis
C6786	Clinical isolate from Oklahoma [40]	128	10/10 survivors at 107 cfu [16]
E0147	Clinical isolate from Georgia [41]	128	10/10 survivors at 107 cfu [16]

Description of the Burkholderia strains used in this study, their susceptibility to kanamycin as described by the minimum inhibitory concentration (MIC) and a summary of published data on virulence of these isolates in mice described as the median lethal dose (MLD) in colony forming units or as number of survivors.